Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Research

A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences

Authors: Yoshiko Tominaga, Donald E. Morisky, Mayumi Mochizuki

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Although diabetes is one of the fastest increasing diseases in prevalence worldwide and demands significant medical resources, more than half of all patients with diabetes do not achieve the expected target level of blood glucose. As a potential cause of poor glycemic control, insufficient adherence to medication has long been discussed and variably studied. However, dropout from treatment as another plausible cause has not been fully examined. The aim of this study was to clarify profiles of patients with diabetes who discontinued pharmacotherapy (Discont group) by extracting reasons of their decisions and by comparing with those who continued (Cont group) in terms of the related factors to glycemic control.

Methods

A cross-sectional, internet-based survey was conducted among Japanese with diabetes registered in a database. A self-administered questionnaire consisting of the 8-item version of the Morisky Medication Adherence Scale (MMAS-8), glycosylated haemoglobin (HbA1c) level, and demographic and disease characteristics was completed by all participants. Reasons for medication discontinuation and resumption were also received retrospectively from participants in the Discont group. To examine the risk of uncontrolled HbA1c, logistic regression analysis was conducted in each group.

Results

In the Discont group (148 cases), older age at resumption of pharmacotherapy and current smoking habit increased the probability of uncontrolled HbA1c, whereas in the Cont group (146 cases), a familial history of diabetes and better medication adherence in MMAS-8 scores decreased the probability of uncontrolled HbA1c. A relationship between medication adherence and HbA1c level was seen in the Cont but not in the Discont group. About 70 % of those in the Discont group made their decision to terminate diabetes treatment without consulting physicians and half of them perceived their situations inappropriately.

Conclusions

Those who discontinued pharmacotherapy were less adherent to medication than those who did not discontinue. Risk factors for glycemic control also differed between those who discontinued and those who did not. More than one-third of participants with diabetes who discontinued pharmacotherapy had inappropriate perceptions of their disease, which medical professionals should be aware of for better interventions.
Literature
11.
go back to reference Hayashino Y, Suzuki H, Yamazaki K, Goto A, Izumi K, Noda M. A cluster randomized trial on the effect of a multifaceted intervention improved the technical quality of diabetes care by primary care physicians: The Japan Diabetes Outcome Intervention Trial-2 (J-DOIT2). Diabet Med 2016; 33:599–608. doi:https://doi.org/10.1111/dme.12949.CrossRefPubMed Hayashino Y, Suzuki H, Yamazaki K, Goto A, Izumi K, Noda M. A cluster randomized trial on the effect of a multifaceted intervention improved the technical quality of diabetes care by primary care physicians: The Japan Diabetes Outcome Intervention Trial-2 (J-DOIT2). Diabet Med 2016; 33:599–608. doi:https://​doi.​org/​10.​1111/​dme.​12949.CrossRefPubMed
12.
go back to reference Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication Adherence Measure for Hypertension Control. J Clin Hyperten 2008; 10:348–354. Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication Adherence Measure for Hypertension Control. J Clin Hyperten 2008; 10:348–354.
17.
go back to reference Gucciardi E. A Systematic Review of Attrition from Diabetes Education Services: Strategies to Improve Attrition and Retention Research. Canadian J Diabetes 2008; 32:53–65.CrossRef Gucciardi E. A Systematic Review of Attrition from Diabetes Education Services: Strategies to Improve Attrition and Retention Research. Canadian J Diabetes 2008; 32:53–65.CrossRef
20.
22.
go back to reference Heianza Y, Arase Y, Saito K, Hsieh SD, Tsuji H, Kodama S, et al. Development of a Screening Score for Undiagnosed Diabetes and Its Application in Estimating Absolute Risk of Future Type 2 Diabetes in Japan: Toranomon Hospital Health Management Center Study 10 (TOPICS 10). J Clin Endocrinol Metab 2013; 98:1051–1060. doi: https://doi.org/10.1210/jc.2012-3092.CrossRefPubMed Heianza Y, Arase Y, Saito K, Hsieh SD, Tsuji H, Kodama S, et al. Development of a Screening Score for Undiagnosed Diabetes and Its Application in Estimating Absolute Risk of Future Type 2 Diabetes in Japan: Toranomon Hospital Health Management Center Study 10 (TOPICS 10). J Clin Endocrinol Metab 2013; 98:1051–1060. doi: https://​doi.​org/​10.​1210/​jc.​2012-3092.CrossRefPubMed
25.
go back to reference Goto K, Shinozaki I, Ishihara T, Kaiho F, Hanawa T. Evaluation of Community Pharmacist Training on Patients’ Non-Verbal Communication. Jpn J Pharm Health Care Sci 2015; 41:66–79.CrossRef Goto K, Shinozaki I, Ishihara T, Kaiho F, Hanawa T. Evaluation of Community Pharmacist Training on Patients’ Non-Verbal Communication. Jpn J Pharm Health Care Sci 2015; 41:66–79.CrossRef
27.
go back to reference Kehneman D. Thinking, fast and slow. New York: Farrar, Straus, and Giroux; 2011. Kehneman D. Thinking, fast and slow. New York: Farrar, Straus, and Giroux; 2011.
28.
go back to reference Kang MI, Ikeda S. Time discounting, present biases, and health-related behaviors: Evidence from Japan. Econ Hum Biol 2016; 21:122–136.CrossRef Kang MI, Ikeda S. Time discounting, present biases, and health-related behaviors: Evidence from Japan. Econ Hum Biol 2016; 21:122–136.CrossRef
Metadata
Title
A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences
Authors
Yoshiko Tominaga
Donald E. Morisky
Mayumi Mochizuki
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00778-7

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine